Preclinical studies using murine models demonstrated that cardiomyocyte-specific modulation of STAT3 activity can attenuate myocardial inflammation and improve cardiac output, with ginsenoside-Rc and other compounds showing promising effects via the STAT3/FoxO3a/SIRT1 axis [82, 83]. The gene discussed is STAT3; the disease is inflammation.